In many laboratories, it is the point at which the more consequential question begins: will this organism respond to a macrolide, or is resistance already written into its ribosomal RNA?
That distinction matters because empiric treatment can look efficient while quietly setting up failure. M. genitalium is difficult to culture, slow to recover, and increasingly shaped by antimicrobial resistance. A molecular test that detects the organism and reflexes positive specimens into a macrolide-resistance assay gives the laboratory a more useful answer than organism identification alone. It connects the result to the next clinical decision.
I find this shift especially important at the bench level. The workflow may appear simple on paper—detect, reflex, report—but every stage carries nuance: specimen type, low organism burden, assay design, mutation nomenclature, reflex rules, and the wording that reaches the treating clinician.
The shift from empiric treatment to resistance-guided therapy
For years, the practical temptation with sexually transmitted infections was to treat first and resolve the details later. That approach becomes much less comfortable with M. genitalium. The organism is not reliably handled by the same assumptions used for more familiar urogenital pathogens, and antimicrobial exposure can select for resistance when the regimen is poorly matched to the strain.
Macrolide resistance in M. genitalium is primarily associated with single-nucleotide polymorphisms in region V of the 23S rRNA gene. The most commonly discussed positions are 2058 and 2059 using E. coli numbering. Some assay materials and clinical references use M. genitalium-specific numbering, including A2071 and A2072. The naming system can look like a minor reporting detail, but it is a real source of confusion when laboratory reports, validation documents, and treatment guidelines use different conventions.
The clinical consequence is much larger than the nomenclature. When resistance-guided therapy is used, reported first-line cure rates have increased from approximately 60% to more than 90%. That improvement is not simply a laboratory success. It represents fewer treatment failures, fewer repeated clinical visits, less pressure to prescribe blindly, and a better chance of interrupting ongoing transmission.
A positive M. genitalium NAAT identifies the organism; reflex resistance testing helps identify the treatment path.
This is why a Mycoplasma genitalium macrolide resistance testing strategy should not be treated as an optional add-on to a standard STI panel. It is a way of aligning the laboratory result with the biology of the organism.
That does not mean every patient requires testing. Major clinical guidance recommends diagnostic testing primarily for patients with persistent or recurrent urethritis, cervicitis, pelvic inflammatory disease, or ongoing sexual partners of people diagnosed with M. genitalium. Routine screening of asymptomatic individuals is not generally recommended. The laboratory’s role begins with an appropriate clinical indication, not with indiscriminate expansion of molecular testing.
What the resistance assay is actually looking for
The molecular target is not resistance in the abstract. It is a defined set of sequence changes in the 23S rRNA gene.
Macrolides act by binding to the bacterial ribosome and interfering with protein synthesis. When particular substitutions occur in the relevant region of the 23S rRNA gene, the drug may bind less effectively. The organism can then persist despite exposure to a macrolide regimen that would otherwise be expected to work.
For a clinical microbiology laboratory, this creates two linked but distinct analytical tasks:
1. Detect M. genitalium nucleic acid.
A nucleic acid amplification test identifies the organism in the specimen. Because culture is extremely difficult and slow, NAAT is the primary diagnostic approach.
2. Characterize macrolide-resistance-associated mutations.
If the organism is detected, a reflex assay examines the relevant 23S rRNA region for mutations associated with macrolide resistance.
The reflex design matters. If resistance analysis is ordered only after a clinician notices a positive result, there may be delays in treatment selection, additional specimen handling, and the possibility that the resistance test is forgotten altogether. A validated reflex pathway makes the second question part of the first diagnostic encounter.
The assay should not be described as measuring the organism’s full antimicrobial susceptibility profile. It detects known genetic markers associated with macrolide resistance. That is a powerful and clinically useful result, but it is still a targeted result. It does not automatically establish susceptibility to every alternative drug, and it does not replace clinical assessment of treatment history, symptoms, reinfection risk, or follow-up testing.
Mutation reporting requires discipline
A good report should make the result readable to someone who is not standing beside the amplification curves. At minimum, the laboratory should distinguish among:
- M. genitalium not detected;
- M. genitalium detected with no macrolide-resistance-associated mutation detected;
- M. genitalium detected with a macrolide-resistance-associated mutation detected;
- organism detected, but resistance result invalid, indeterminate, or unavailable.
The final category is particularly important. A positive organism result with an unsuccessful resistance call is not equivalent to a susceptible result. The report should preserve that distinction rather than forcing an apparently clean interpretation from incomplete data.
Assay documentation should also clarify which mutations are included, how the laboratory handles uncommon sequence variants, and whether the resistance target is amplified independently or through a combined design. A test can be analytically impressive and still create clinical ambiguity if its result categories are not mapped carefully to the treatment algorithm.
Diagnostic workflow: from NAAT detection to reflex profiling
The molecular workflow begins before amplification. Specimen collection and transport influence whether the assay has enough target material to produce a reliable result. Low organism burden, inappropriate collection, delays in transport, and inhibitors can all turn a straightforward reflex pathway into an interpretive problem.
In practice, the workflow is best understood as a series of decision points rather than a single test.
1. Confirm the clinical indication and specimen pathway
The test request should identify the clinical context when possible: persistent urethritis, recurrent cervicitis, pelvic inflammatory disease, suspected treatment failure, or contact with a diagnosed partner. This information does not change the molecular chemistry, but it changes how the result will be used.
The laboratory also needs a defined specimen policy. Collection devices, transport media, specimen stability, and acceptable anatomic sites should be consistent with the assay’s validation. A reflex test is only as reliable as the specimen that reaches it.
2. Run the organism-detection NAAT
The initial NAAT should include the usual internal controls and validity checks required by the platform. A negative result means the target was not detected under the conditions of the assay; it does not mean that every possible cause of urethritis, cervicitis, or pelvic pain has been excluded.
A positive result triggers the reflex step. Laboratories should decide in advance whether this occurs automatically on the same specimen, from a retained aliquot, or through a separate molecular procedure. Each model has operational consequences for staffing, storage, batching, and turnaround time.
3. Perform the 23S rRNA resistance assay
The M. genitalium resistance reflex assay then evaluates the relevant 23S rRNA region. The laboratory should monitor whether the resistance target amplifies adequately in positive specimens and should have a clear rule for discordant or failed results.
A positive organism result with an invalid resistance assay may require repeat testing if sufficient specimen remains. If no material is available, the report should say so plainly. The phrase “no resistance detected” should be reserved for a valid assay result—not used as a polite substitute for “unable to determine.”
4. Release a result that supports action
The final report should connect the molecular finding to the clinical protocol without pretending that the laboratory is prescribing. A concise interpretive comment can explain that detection of a macrolide-resistance-associated mutation supports selection of a nonmacrolide regimen under applicable clinical guidance, while absence of a detected mutation supports the macrolide-sensitive pathway when the full clinical picture agrees.
That comment is not administrative decoration. In a busy clinic, it may be the only part of the result that receives close attention.
| Laboratory result | What it establishes | What it does not establish |
|---|---|---|
| M. genitalium not detected | The organism’s target was not detected in the submitted specimen | It does not exclude other causes of symptoms or infection outside the assay’s scope |
| Organism detected; resistance mutation not detected | No tested macrolide-resistance-associated mutation was identified | It does not guarantee clinical cure or exclude resistance mechanisms outside the assay |
| Organism detected; resistance mutation detected | A tested 23S rRNA mutation associated with macrolide resistance is present | It does not by itself determine the full alternative-drug susceptibility profile |
| Organism detected; resistance result invalid or indeterminate | The organism was detected, but resistance status could not be resolved | It should not be reported as susceptible or resistant by assumption |
The treatment pathway depends on the reflex result
The laboratory result becomes clinically useful when it is connected to a defined treatment pathway. Current protocols described in the supplied guidance use an initial doxycycline course followed by a resistance-directed agent.
For macrolide-sensitive infections, the protocol specifies doxycycline at 100 mg twice daily for 7 days, followed by azithromycin: a 1 g initial dose and then 500 mg daily for 3 additional days.
When a macrolide-resistance mutation is detected, the protocol recommends doxycycline at 100 mg twice daily for 7 days followed by moxifloxacin at 400 mg daily for 7 to 14 days.
The sequencing is worth emphasizing. Single-dose azithromycin alone should not be treated as a universal solution, particularly when macrolide resistance is present. The reflex result exists precisely because the organism’s resistance status changes the logic of therapy.
A clinical report can therefore be structured around the decision that follows:
- Macrolide-resistance-associated mutation not detected: follow the macrolide-sensitive treatment pathway when clinically appropriate.
- Macrolide-resistance-associated mutation detected: avoid the macrolide-directed pathway and follow the recommended alternative regimen.
- Resistance result unavailable: do not infer susceptibility; communicate the limitation and use the appropriate clinical alternative.
Treatment history also matters. A patient with persistent symptoms after therapy may have reinfection, inadequate adherence, an untreated partner, an alternative diagnosis, or genuine antimicrobial failure. The molecular result narrows the problem, but it does not solve every part of it.
This is where the laboratory and clinic need a shared language. A report that says only “mutation detected” may be technically correct but operationally incomplete. A report that overstates the finding as proof of treatment failure may be clinically misleading. The best wording is direct, bounded, and connected to the guideline pathway.
Why culture is not the practical fallback
In many areas of clinical microbiology, culture remains the familiar reference point. It gives the bench a living organism, an opportunity to observe growth, and—in some settings—a route toward phenotypic susceptibility testing. M. genitalium is a different kind of problem.
Culture is extremely difficult and slow, with a turnaround time of approximately 3 to 6 weeks and reported clinical sensitivity in the range of 20% to 50%. That combination makes it poorly suited to routine clinical decision-making for suspected M. genitalium infection.
The issue is not merely that culture takes patience. A negative culture can reflect the limitations of recovery rather than the absence of infection. The organism’s fastidious nature, low abundance, and demanding growth requirements make the process vulnerable at every stage. By the time a result is available, the immediate treatment decision has usually already passed.
This is one of those cases where molecular diagnostics do not erase the value of traditional microbiology; they answer a different practical need. The NAAT detects the organism when culture is unlikely to be timely or sensitive enough. The resistance assay then adds a genomic layer that can guide therapy without waiting for growth.
For bench technologists, that does not mean the molecular workflow is effortless. Reflex testing requires careful specimen tracking, reliable rules for aliquot retention, control review, and clear escalation when the resistance component fails. The hands-on work has moved; it has not disappeared.
The most useful reflex pathway is not the one with the most targets. It is the one that reliably turns a positive result into the next defensible decision.
Where the workflow can fail
A reflex assay is often described as an efficiency improvement, but automation does not remove the need for judgment. It shifts judgment into the design and maintenance of the pathway.
Several failure points deserve attention.
The positive result does not trigger reflex testing
This can happen when the organism-detection assay and the resistance assay are ordered separately, when the electronic health record does not carry the reflex instruction correctly, or when a result is released before the second stage begins. The solution is operational: define the reflex rule in the laboratory information system, confirm specimen retention, and monitor the interval between organism detection and resistance reporting.
The specimen is positive but too weak for resistance analysis
A low-level positive may be sufficient for organism detection but insufficient for a reliable resistance call. Laboratories should avoid treating this as a simple negative. The correct status may be “detected; resistance indeterminate,” followed by a comment about repeat collection or clinical correlation where appropriate.
Mutation nomenclature creates confusion
Reports, package inserts, and guidelines may use different numbering conventions for the same resistance-associated region. The laboratory should identify the convention used in its report and, where needed, include equivalent nomenclature in validation or interpretive documentation. A clinician should not have to decode whether two apparently different mutation labels refer to the same biological finding.
Resistance is treated as a complete susceptibility profile
A positive 23S rRNA mutation result supports the conclusion that a macrolide-directed regimen may be inappropriate. It does not automatically describe fluoroquinolone susceptibility or every possible resistance mechanism. Available evidence has reported fluoroquinolone resistance in urban settings at approximately 20%, while the exact global prevalence of concurrent resistance mutations remains uncertain in some populations. That uncertainty belongs in the laboratory’s internal risk assessment and in clinical discussion—not hidden behind an overly broad report comment.
A negative result is overinterpreted
The assay’s performance is affected by specimen quality, organism burden, and the clinical context. A negative M. genitalium NAAT does not turn every symptom into a noninfectious complaint, and it does not replace evaluation for other pathogens or causes of inflammation.
These are not theoretical distinctions. They are the small points at which a clean molecular workflow can become a messy clinical conversation.
Resistance patterns make reflex testing more consequential
The value of reflex testing rises as resistance becomes more common. In Australia, macrolide resistance has been reported in more than 60% of general cases and more than 80% among men who have sex with men. Those figures should not be exported uncritically to every population or laboratory catchment area, but they illustrate why a universal empiric macrolide assumption is increasingly difficult to defend.
The laboratory does not need to turn every report into an epidemiology lecture. It does need to recognize that local resistance patterns influence the clinical value of the assay. A reflex program in a setting with substantial macrolide resistance is not simply adding another molecular target; it is reducing the number of treatment decisions made without relevant microbiological information.
At the same time, resistance prevalence should not become a reason to test outside the recommended clinical indications. The right response to resistance is better-targeted testing and treatment, not indiscriminate screening. That distinction protects patients from unnecessary diagnosis and protects laboratories from building high-volume workflows with limited clinical yield.
Building a report clinicians can use
A useful report should be accurate enough for the microbiologist, clear enough for the prescribing clinician, and restrained enough to avoid making claims beyond the assay.
I would expect the reporting pathway to address five practical questions:
1. Was M. genitalium detected?
State the organism result plainly and separate it visually or conceptually from the resistance result.
2. Was the resistance assay performed successfully?
Make “not detected,” “indeterminate,” and “not performed” distinct categories.
3. Which mutation interpretation applies?
Identify that the result concerns tested macrolide-resistance-associated mutations in the 23S rRNA gene.
4. What clinical pathway does the result support?
Refer to the relevant sensitive or resistant treatment pathway without presenting the laboratory as the final prescribing authority.
5. What remains outside the assay?
Briefly note that the result does not assess every antimicrobial resistance mechanism or explain every cause of symptoms.
The wording should also be consistent across platforms. If one assay reports “wild type,” another reports “no mutation detected,” and a third reports “macrolide susceptible,” clinicians may interpret equivalent findings differently. Standardized terminology reduces that friction.
For laboratories developing or revising a M. genitalium 23S rRNA mutation panel, validation should include more than analytical sensitivity. It should examine invalid rates, low-level positives, specimen carryover, reflex completion, mutation coverage, report language, and the time from detection to actionable result. A test that performs well in a controlled run but regularly produces unresolved clinical reports is not meeting the whole need.
The practical meaning of molecular STI resistance reflex testing
The larger lesson extends beyond M. genitalium. Molecular testing is most valuable when it answers the question the clinician actually faces.
Detection alone may be enough for one pathogen. For another, detection without resistance information leaves the treatment decision only partly informed. The challenge is to know which problem the assay is solving and to design the workflow around that problem.
In M. genitalium, the logic is unusually clear:
- culture is too slow and insensitive for routine clinical decisions;
- NAAT provides the primary route to organism detection;
- 23S rRNA mutation analysis identifies a major macrolide-resistance signal;
- reflex testing can improve first-line cure rates from roughly 60% to more than 90%;
- the report must distinguish a valid negative resistance result from an unresolved one;
- clinical indications still matter, and asymptomatic universal screening is not the recommended default.
That is a compact algorithm, but it depends on careful laboratory work. Someone has to verify the specimen, review the controls, track the reflex, investigate the invalid, and make sure the final report says exactly what the assay can support.
The bench-level takeaway
Mycoplasma genitalium reflex testing is not just a more sophisticated version of a positive STI result. It is a change in diagnostic posture: from identifying an organism and hoping the standard regimen works to identifying the organism and asking which treatment pathway its resistance profile permits.
For laboratory teams, the next steps are practical. Build the reflex rule into the order and specimen workflow. Validate the mutation targets and numbering conventions. Separate “no mutation detected” from “resistance unresolved.” Make the interpretive comment useful without overstating the assay. Keep culture’s limitations visible. And remember that a molecular result is only as good as the clinical decision it enables.
The most reassuring outcome is not simply a detected organism, a clean amplification curve, or a rapidly released report. It is a result that arrives in time, carries the right level of certainty, and helps a clinician avoid treating resistance as a surprise.